

Development of a Recombinant Antibody with Specificity for Chelated Uranyl Ions

X Li¹, A.M. Kriegel¹, T.C. Bishop², R.C. Blake II³, E. Figueiredo¹, H. Yu¹, and D.A. Blake¹

Departments of ¹Biochemistry and ²Environmental Health Sciences, Tulane Univ. Hlth. Sci. Ctr., New Orleans, LA 70112, ³College of Pharmacy, Xavier University of Louisiana, New Orleans, LA 70125 Tel:504-988-2478; Fax:504-988-2739; email: blake@tulane.edu

Abstract

The goal of our project is to continue the development of new techniques for rapid automated identification of radiotracers, metals, and clusters that may contaminate surfaces and groundwater at DOE sites. One of our specific aims of the present project is to develop new technologies in antibody engineering that will enhance our immunotherapy program. Recombinant antibodies have potential advantages over monoclonal antibodies produced by standard hybridoma technology. The cloned genes represent a stable, recoverable source for antibody production. In addition, a recombinant form at offer opportunities for protein engineering that enhances antibody performance and for studies that relate antibody sequence to binding activity. In this study, a hybridoma that synthesized an antibody (12F6) that recognized a 1:1 complex between 2,9-dicarboxy-1,10-phenanthroline (DCP) and UO_2^{2+} was used as a source of RNA for the development of a recombinant Fab. The Fab fragment was isolated from the 12F6 hybridoma and the DCP-binding domain was expressed in E. coli. A heavy chain variable fragment (F(ab)₂) was expressed in E. coli and the light chain variable fragment (Fv) was expressed in yeast. The F(ab)₂ fragment was fused to a truncated hinge region and the Fv fragments were ligated into a commercial dicistronic vector (pBudCE4.1, Invitrogen Inc.). COS-1 cells were transfected with this vector and the culture supernatant was assayed for activity and the (Fab)₂ fragment prepared from the native 12F6 antibody in terms of the heavy and light chain variable domains were also used according to the canonical structure in end detailed by Mori et al. (J. Mol. Biol. 272:269), and the participation of specific residues in antigen recognition was assessed using site-directed mutagenesis. Three amino acids in the light chain variable region, H38, Y54 and P103, were particularly important in antigen recognition.

In a separate series of experiments, a recombinant phage-display antibody library has been prepared using RNA isolated from the spleen of sheep and rabbits immunized with specific metal-chelate complexes. Phage-display libraries produced from an immunized sheep are inclined to include variable genes specific for the immunized antigen(s), many of which are already affinity matured. An antibody fragment specific for the UO_2^{2+} -DCP complex was isolated from this combinatorial phage display library. While the binding affinity of this antibody fragment for UO_2^{2+} -DCP was not as high as that of the 12F6 monoclonal antibody, the beauty of antibody phage display technology is that it allows for the potential manipulation and maturation of the antibody's binding affinity, which may drastically improve and ultimately surpass that of monoclonal antibodies.




Figure 1. Diagram of the three most common formats for the expression of recombinant antibodies. Panel A: The single chain variable fragment format, scFv, consists of a hinge region (yellow) and the light chain variable region (red) joined by a flexible linker (blue). Panel B: The scFv format consists of the hinge region (yellow) joined to the light chain variable region (red) via a flexible linker (blue). Panel C: The Fab format consists of the hinge region (yellow), light chain variable region (red), and the constant region (green).

Figure 2. UO_2^{2+} -DCP complex recognized by the recombinant antibodies.




Figure 3. Activity of culture supernatants after transfection with pBudCE-12F6-Fab. The coding region of the light chain and the variable and first constant region of the heavy chain were expressed in yeast. The hinge region and the second constant region of the Fab fragment were expressed in E. coli. The Fab fragment was expressed using a dicistronic vector available from Invitrogen, to yield the plasmid pBudCE-12F6-Fab. Plasmid pBudCE-12F6-Fab was transfected into COS-1 cells using the calcium phosphate precipitation reagent (per μg DNA) in serum-free DMEM. After incubation at room temperature for 20 minutes, the cells were washed with DMEM and then transfected with the calcium phosphate precipitate by adding 10 μl of the solution to each well of a 24-well plate. Transfection was performed for 8 hours at 37°C after which the complexes were removed and replaced with growth media. Transfection proceeded for 36 hours and the culture supernatant was assayed for activity. The absorbance of the soluble UO_2^{2+} -DCP complex to protein binding was assessed by competitive ELISA and the equilibrium/dissociation constants determined. Values are mean \pm SD ($n=3$). Data are expressed as percent of the activity displayed by (Fab)₂, fragment prepared by polymerase chain reaction (PCR) cloning of the 12F6 antibody gene into the included culture supernatant from cells transfected with an empty vector (pBudCE4.1) and untransfected culture supernatant containing 10% fetal bovine serum (DMEM). Values are reported as mean \pm SD ($n=3$).




Figure 4. Binding of wild-type r12F6-Fab and mutants to immobilized UO_2^{2+} -DCP. Mutant clones were constructed according to the canonical framework method detailed in Mori et al. (5) using the Swiss PDB Viewer program (version 3.7). Amino acid residues targeted for site-directed mutagenesis are shown in space-filling format. The hinge region is shown in yellow, the light chain variable region in red, and the entire light chain (yellow). The CDR1, CDR2 and CDR3 are shown in green, blue and orange respectively. The positions of the mutations introduced in the mutants are indicated. The amino acid sequences of the mutants chosen for mutagenesis based on this model are also listed in Table 1, below.




Figure 5. Biochemical and immunological characterization of the different mutants of the r12F6 Fab. Mutants were constructed by sequencing to have only the mutations shown (sequence data not presented). Transfection of the instant plasmids into COS-1 cells using lipofectamine was as described in the legend to Figure 4. The culture supernatants were assayed for activity. The activity was measured by competitive ELISA and the equilibrium/dissociation constants determined. Values are mean \pm SD ($n=3$). Data are expressed as percent of the activity displayed by (Fab)₂, fragment prepared by polymerase chain reaction (PCR) cloning of the 12F6 antibody gene into the included culture supernatant from cells transfected with an empty vector (pBudCE4.1) and untransfected culture supernatant containing 10% fetal bovine serum (DMEM). Values are reported as mean \pm SD ($n=3$).




Figure 6. Ribbon representation of the r12F6-Fab heterology model. Molecular models were constructed according to the canonical framework method detailed in Mori et al. (5) using the Swiss PDB Viewer program (version 3.7). Amino acid residues targeted for site-directed mutagenesis are shown in space-filling format. The hinge region is shown in yellow, the light chain variable region in red, and the entire light chain (yellow). The CDR1, CDR2 and CDR3 are shown in green, blue and orange respectively. The positions of the mutations introduced in the mutants are indicated. The amino acid sequences of the mutants chosen for mutagenesis based on this model are also listed in Table 1, below.




Figure 7. Binding activity of rFab and selected mutants. The concentration dependence of protein binding to UO_2^{2+} -DCP was determined by competitive ELISA. The equilibrium dissociation constant (K_d) is the concentration of soluble UO_2^{2+} -DCP required to reduce the maximum binding of the antibody to half. The equilibrium dissociation constants for the wild-type r12F6-Fab and the mutants H-S104A, H-T107A, and L-Y37A are shown. The data are expressed as mean \pm SD ($n=3$). The asterisk indicates that the K_d value is significantly different from the wild-type K_d ($p < 0.05$).




Figure 7. Polyclonal sheep/goat construction of a recombinant anti-metal-chelate antibody library. Four rabbits and two sheep were immunized with mixtures of metal-chelate-protein conjugates. After the animals had demonstrated immune reactivity in a serum sample, they were sacrificed and their spleens removed. The spleen tissue was homogenized and the IgG fraction isolated. The IgG variable coding regions were amplified by PCR using primers as described in (4). These IgG variable genes were inserted into the pSD3 scFv vector (Invitrogen) to generate the pSD3 scFv libraries. A, B are VL and VH DNA fragments. C and H are c-myc and His tags, respectively. The "x" indicates an amber codon. AgIII is the gene encoding the C-terminal domain of the IgG gene (see panel A).

ScFv-Phage Screening




Figure 8. Results from competitive ELISA screening using scFv-phage particles to metal-chelate protein conjugate or soluble metal-chelate complex. The relative binding of the clones were calculated from the volume of scFv-phage particles bound to the metal-chelate complex over the volume of the inhibitor showed in the legend, then added to a direct competition assay of 20a-DCP + 10 μM UO_2^{2+} . The legend shows the volume of the inhibitor added to a direct competition assay of 20a-DCP + 10 μM UO_2^{2+} . HBS = phosphate-buffered saline. Individual clones were assayed in triplicate with soluble metal-chelate complex and anti-dIgG biotin conjugate and Extended AP substrate (Sigma). Values are mean \pm SD ($n=3$).

UO₂²⁺-DCP Competition Assay




Figure 9. Competition ELISA with soluble UO_2^{2+} -DCP bound to phage particles used for these experiments. K_d values range from 0.19 μM to 0.37 μM for clones 3-1, 3-2, and 3-12.

Conclusions

A monoclonal antibody (12F6) that binds to chelated uranyl ions (see ligand structure in Figure 2) with nanomolar affinity has been expressed as a recombinant Fab fragment.

Molecular modeling and subsequent site-directed mutagenesis have identified several amino acid sidechains (histidine, tyrosine, and phenylalanine) in the light chain variable region that are very important in the interaction between the 12F6 antibody and the UO_2^{2+} -DCP complex.

Interestingly, another mutation in the light chain (methionine of phenylalanine 103 to an alanine residue) slightly increased the affinity of the recombinant antibody for the UO_2^{2+} -DCP complex.

A recombinant library of antibodies to metal-chelate complexes has been prepared from animals immunized with a mixture of metal-chelate complexes.

Preliminary phasing of this library has yielded an antibody fragment that binds to the UO_2^{2+} -DCP complex with micromolar affinity.

These recombinant protein constructs will provide the DOE with a source of antibody reagents that could be genetically manipulated to suit the assessment requirements of specific DOE facilities.

1. E. Figueiredo, R.J. Jones, T.C. Bishop and D.A. Blake (2003) Identification of important residues in metalchelate recognition by monoclonal antibodies. *Biochemistry*, 42:1473-1483
2. R.C. Blake II, R. Pavlov, M. Khosravi, H.E. Ensey, G.E. Kiefer, H. Yu, X. Li, and D.A. Blake (2004) Novel monoclonal antibodies with specificity for chelated uranium(VI) isolation and binding properties. *Bioconjugate Chemistry* 15:1125-1136
3. Mori, V., Tamponi, A., Rustici, M., Chothia, C. & Lasker, A.M. (1997) Antibody structure, prediction and redesign. *Biophysical Chemistry*, 68: 9-16.

Acknowledgments: This work was supported by the Office of Science (DOE) (DE-FG02-03ER15459) and the National Institute of Environmental Health Sciences (NIH) (ES-12262).